HOMERUS: A Local, Open Label, Multicentre, Phase IIIB Study, Investigating Subcutaneous Trastuzumab Administered at Home With Single Injection Device in Patients With HER2-Positive Early Breast Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Trastuzumab (Primary)
- Indications Adenocarcinoma; Early breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational
- Acronyms HOMERUS
- Sponsors Roche
- 21 Sep 2020 Primary and final analysis results presented at the 45th European Society for Medical Oncology Congress
- 07 Aug 2018 Status changed from active, no longer recruiting to completed.
- 02 May 2017 Planned End Date changed from 1 Jul 2018 to 6 Jul 2018.